The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Beyond the Liver: Milk Thistle’s 4 Extra Benefits

Back to News Homepage

Next

The Link Between Hep C and Parkinson’s Disease

Daklinza and Sovaldi to Treat Hep C Genotype 1

February 11, 2016

Print this page

Find out the details of the updated drug label.

FDA Expands Daklinza/Sovaldi Approval to Include Treatment of Hepatitis C Genotype 1

February 10, 2016

The U.S. Food and Drug Administration (FDA) has expanded the approved uses of the combination hepatitis C virus (HCV) regimen of Bristol-Myers Squibb’s (BMS) Daklinza (daclatasvir) and Gilead Sciences’ Sovaldi (sofosbuvir). Approved to treat genotype 3 of the virus in July 2015, the regimen may now treat genotype 1, as well as individuals with advanced cirrhosis and people whose hep C has returned after a liver transplant.

Continue reading this entire article:
http://www.aidsmeds.com/articles/Daklinza_Sovaldi_1667_28349.shtml

 

No Comments - be the first!
Share
Share

Previous

Beyond the Liver: Milk Thistle’s 4 Extra Benefits

Back to News Homepage

Next

The Link Between Hep C and Parkinson’s Disease

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.

Comments are closed here.